40 results on '"Hendren, N."'
Search Results
2. Complex Management of a Young Cardiomyopathy Patient Leading to Durable LVAD
- Author
-
Tan, Y., primary, Malik, T., additional, Hendren, N., additional, Hardin, E., additional, Teotia, S., additional, Reznik, S., additional, Farr, M., additional, and Peltz, M., additional
- Published
- 2024
- Full Text
- View/download PDF
3. Characteristics and Outcomes of Patients Receiving Advanced Heart Failure Therapies from a Safety-Net Hospital in the United States
- Author
-
Hendren, N., primary, Carter, S., additional, Truby, L., additional, Nixon, J., additional, Hussain, F., additional, Jawaid, A., additional, Wrobel, C., additional, Hardin, E., additional, Garg, S., additional, Grodin, J., additional, Morlend, R., additional, Thibodeau, J., additional, Araj, F., additional, Drazner, M., additional, Peltz, M., additional, De Lemos, J., additional, Das, S., additional, and Farr, M., additional
- Published
- 2024
- Full Text
- View/download PDF
4. Pulseless Paradoxus in a Heartmate3 Recipient with Cardiac Tamponade
- Author
-
Beaini, H., primary, Hussain, F., additional, Jawaid, A., additional, Truby, L., additional, Ginder, K., additional, Zimmerman, R., additional, Waller, S., additional, Josey, A., additional, Goral, M., additional, Thomas, M., additional, Varghese, D., additional, Edwards, M., additional, Hendren, N., additional, Peltz, M., additional, Farr, M., additional, and Araj, F., additional
- Published
- 2024
- Full Text
- View/download PDF
5. Glucagon-Like Peptide-1 Agonist Use for Obesity Treatment in Patients with Left Ventricular Assist Devices
- Author
-
Edwards, M., primary, Thomas, M., additional, Varghese, D., additional, Truby, L., additional, Wrobel, C., additional, Hardin, E., additional, Thibodeau, J., additional, Drazner, M., additional, Peltz, M., additional, Farr, M., additional, Grodin, J., additional, and Hendren, N., additional
- Published
- 2024
- Full Text
- View/download PDF
6. Association of HLA Mismatch and Treatment for Rejection within the First Year After Heart Transplantation
- Author
-
Truby, L.K., primary, Jawaid, A., additional, Hussain, F., additional, Wrobel, C., additional, Hendren, N., additional, Garg, S., additional, Morlend, R., additional, Beaini, H., additional, Hardin, E., additional, Araj, F., additional, Thibodeau, J.T., additional, Drazner, M., additional, Grodin, J.L., additional, Lacelle, C., additional, Peltz, M., additional, and Farr, M., additional
- Published
- 2024
- Full Text
- View/download PDF
7. The Forgotten Pump - Waitlist & Post-Transplant Outcomes of Heart Transplant Recipients Supported by Heartware HVAD Before & After Device Recall
- Author
-
Hussain, F., primary, Jawaid, A., additional, Morlend, R., additional, Thomas, M., additional, Hendren, N., additional, Weston, J., additional, Heid, C., additional, Ginder, K., additional, Hardin, E., additional, Araj, F., additional, Farr, M., additional, Peltz, M., additional, and Truby, L., additional
- Published
- 2024
- Full Text
- View/download PDF
8. Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis
- Author
-
Ammirati, E, Lupi, L, Palazzini, M, Hendren, N, Grodin, J, Cannistraci, C, Schmidt, M, Hekimian, G, Peretto, G, Bochaton, T, Hayek, A, Piriou, N, Leonardi, S, Guida, S, Turco, A, Sala, S, Uribarri, A, Van De Heyning, C, Mapelli, M, Campodonico, J, Pedrotti, P, Barrionuevo Sanchez, M, Ariza Sole, A, Marini, M, Matassini, M, Vourc'H, M, Cannata, A, Bromage, D, Briguglia, D, Salamanca, J, Diez-Villanueva, P, Lehtonen, J, Huang, F, Russel, S, Soriano, F, Turrini, F, Cipriani, M, Bramerio, M, Di Pasquale, M, Grosu, A, Senni, M, Farina, D, Agostoni, P, Rizzo, S, De Gaspari, M, Marzo, F, Duran, J, Adler, E, Giannattasio, C, Basso, C, Mcdonagh, T, Kerneis, M, Combes, A, Camici, P, De Lemos, J, Metra, M, Ammirati E., Lupi L., Palazzini M., Hendren N. S., Grodin J. L., Cannistraci C. V., Schmidt M., Hekimian G., Peretto G., Bochaton T., Hayek A., Piriou N., Leonardi S., Guida S., Turco A., Sala S., Uribarri A., Van De Heyning C. M., Mapelli M., Campodonico J., Pedrotti P., Barrionuevo Sanchez M. I., Ariza Sole A., Marini M., Matassini M. V., Vourc'H M., Cannata A., Bromage D. I., Briguglia D., Salamanca J., Diez-Villanueva P., Lehtonen J., Huang F., Russel S., Soriano F., Turrini F., Cipriani M., Bramerio M., Di Pasquale M., Grosu A., Senni M., Farina D., Agostoni P., Rizzo S., De Gaspari M., Marzo F., Duran J. M., Adler E. D., Giannattasio C., Basso C., McDonagh T., Kerneis M., Combes A., Camici P. G., De Lemos J. A., Metra M., Ammirati, E, Lupi, L, Palazzini, M, Hendren, N, Grodin, J, Cannistraci, C, Schmidt, M, Hekimian, G, Peretto, G, Bochaton, T, Hayek, A, Piriou, N, Leonardi, S, Guida, S, Turco, A, Sala, S, Uribarri, A, Van De Heyning, C, Mapelli, M, Campodonico, J, Pedrotti, P, Barrionuevo Sanchez, M, Ariza Sole, A, Marini, M, Matassini, M, Vourc'H, M, Cannata, A, Bromage, D, Briguglia, D, Salamanca, J, Diez-Villanueva, P, Lehtonen, J, Huang, F, Russel, S, Soriano, F, Turrini, F, Cipriani, M, Bramerio, M, Di Pasquale, M, Grosu, A, Senni, M, Farina, D, Agostoni, P, Rizzo, S, De Gaspari, M, Marzo, F, Duran, J, Adler, E, Giannattasio, C, Basso, C, Mcdonagh, T, Kerneis, M, Combes, A, Camici, P, De Lemos, J, Metra, M, Ammirati E., Lupi L., Palazzini M., Hendren N. S., Grodin J. L., Cannistraci C. V., Schmidt M., Hekimian G., Peretto G., Bochaton T., Hayek A., Piriou N., Leonardi S., Guida S., Turco A., Sala S., Uribarri A., Van De Heyning C. M., Mapelli M., Campodonico J., Pedrotti P., Barrionuevo Sanchez M. I., Ariza Sole A., Marini M., Matassini M. V., Vourc'H M., Cannata A., Bromage D. I., Briguglia D., Salamanca J., Diez-Villanueva P., Lehtonen J., Huang F., Russel S., Soriano F., Turrini F., Cipriani M., Bramerio M., Di Pasquale M., Grosu A., Senni M., Farina D., Agostoni P., Rizzo S., De Gaspari M., Marzo F., Duran J. M., Adler E. D., Giannattasio C., Basso C., McDonagh T., Kerneis M., Combes A., Camici P. G., De Lemos J. A., and Metra M.
- Abstract
Background: Acute myocarditis (AM) is thought to be a rare cardiovascular complication of COVID-19, although minimal data are available beyond case reports. We aim to report the prevalence, baseline characteristics, in-hospital management, and outcomes for patients with COVID-19-associated AM on the basis of a retrospective cohort from 23 hospitals in the United States and Europe. Methods: A total of 112 patients with suspected AM from 56 963 hospitalized patients with COVID-19 were evaluated between February 1, 2020, and April 30, 2021. Inclusion criteria were hospitalization for COVID-19 and a diagnosis of AM on the basis of endomyocardial biopsy or increased troponin level plus typical signs of AM on cardiac magnetic resonance imaging. We identified 97 patients with possible AM, and among them, 54 patients with definite/probable AM supported by endomyocardial biopsy in 17 (31.5%) patients or magnetic resonance imaging in 50 (92.6%). We analyzed patient characteristics, treatments, and outcomes among all COVID-19-associated AM. Results: AM prevalence among hospitalized patients with COVID-19 was 2.4 per 1000 hospitalizations considering definite/probable and 4.1 per 1000 considering also possible AM. The median age of definite/probable cases was 38 years, and 38.9% were female. On admission, chest pain and dyspnea were the most frequent symptoms (55.5% and 53.7%, respectively). Thirty-one cases (57.4%) occurred in the absence of COVID-19-associated pneumonia. Twenty-one (38.9%) had a fulminant presentation requiring inotropic support or temporary mechanical circulatory support. The composite of in-hospital mortality or temporary mechanical circulatory support occurred in 20.4%. At 120 days, estimated mortality was 6.6%, 15.1% in patients with associated pneumonia versus 0% in patients without pneumonia (P=0.044). During hospitalization, left ventricular ejection fraction, assessed by echocardiography, improved from a median of 40% on admission to 55% at discharge
- Published
- 2022
9. P408 PREVALENCE CHARACTERISTICS AND OUTCOMES OF COVID 19 ASSOCIATED ACUTE MYOCARDITIS
- Author
-
Palazzini, M, primary, Ammirati, E, additional, Lupi, L, additional, Giannattasio, C, additional, Soriano, F, additional, Pedrotti, P, additional, Briguglia, D, additional, Mapelli, M, additional, Campodonico, J, additional, Agostoni, P, additional, Leonardi, S, additional, Turco, A, additional, Guida, S, additional, Peretto, G, additional, Sala, S, additional, Camici, P, additional, Marzo, F, additional, Grosu, A, additional, Senni, M, additional, Turrini, F, additional, Bramerio, M, additional, Marini, M, additional, Matassini, M, additional, Rizzo, S, additional, Basso, C, additional, De Gaspari, M, additional, Hendren, N, additional, Schmidt, M, additional, Bochaton, T, additional, Piriou, N, additional, Ubarri, A, additional, Van De Heyning, C, additional, Ariza Sole, A, additional, Cannatà, A, additional, Salamanca, J, additional, Lehtonen, J, additional, Huang, F, additional, Adler, E, additional, and Metra, M, additional
- Published
- 2023
- Full Text
- View/download PDF
10. (823) Survival of the Unfittest: The Longest Living LVAD-Supported Patient with DMD-Associated Cardiomyopathy
- Author
-
Godfrey, S., primary, Araj, F., additional, Hendren, N., additional, Amin, A., additional, Hardin, E., additional, Garg, S., additional, Grodin, J., additional, Morlend, R., additional, Thibodeau, J., additional, Peltz, M., additional, Drazner, M., additional, Farr, M., additional, and Mammen, P., additional
- Published
- 2023
- Full Text
- View/download PDF
11. (829) - The Forgotten Pump - Waitlist & Post-Transplant Outcomes of Heart Transplant Recipients Supported by Heartware HVAD Before & After Device Recall
- Author
-
Jawaid, A., Morlend, R., Thomas, M., Hendren, N., Weston, J., Heid, C., Ginder, K., Hardin, E., Araj, F., Farr, M., Peltz, M., and Truby, L.
- Published
- 2024
- Full Text
- View/download PDF
12. (438) - Impact of the 2018 Heart Transplant System Allocation Change on Older Adults
- Author
-
Godfrey, S., Gorrai, A., Garg, S., Hendren, N., Wrobel, C., Hardin, E., Drazner, M., Peltz, M., and Farr, M.
- Published
- 2024
- Full Text
- View/download PDF
13. (1291) - Complex Management of a Young Cardiomyopathy Patient Leading to Durable LVAD
- Author
-
Malik, T., Hendren, N., Hardin, E., Teotia, S., Reznik, S., Farr, M., and Peltz, M.
- Published
- 2024
- Full Text
- View/download PDF
14. (1192) - Pulseless Paradoxus in a Heartmate3 Recipient with Cardiac Tamponade
- Author
-
Hussain, F., Jawaid, A., Truby, L., Ginder, K., Zimmerman, R., Waller, S., Josey, A., Goral, M., Thomas, M., Varghese, D., Edwards, M., Hendren, N., Peltz, M., Farr, M., and Araj, F.
- Published
- 2024
- Full Text
- View/download PDF
15. (1082) - Characteristics and Outcomes of Patients Receiving Advanced Heart Failure Therapies from a Safety-Net Hospital in the United States
- Author
-
Hendren, N., Carter, S., Truby, L., Nixon, J., Hussain, F., Wrobel, C., Hardin, E., Garg, S., Grodin, J., Morlend, R., Thibodeau, J., Araj, F., Drazner, M., Peltz, M., De Lemos, J., Das, S., and Farr, M.
- Published
- 2024
- Full Text
- View/download PDF
16. (341) - Association of HLA Mismatch and Treatment for Rejection within the First Year After Heart Transplantation
- Author
-
Jawaid, A., Hussain, F., Wrobel, C., Hendren, N., Garg, S., Morlend, R., Beaini, H., Hardin, E., Araj, F., Thibodeau, J.T., Drazner, M., Grodin, J.L., Lacelle, C., Peltz, M., and Farr, M.
- Published
- 2024
- Full Text
- View/download PDF
17. (30) - Glucagon-Like Peptide-1 Agonist Use for Obesity Treatment in Patients with Left Ventricular Assist Devices
- Author
-
Thomas, M., Varghese, D., Truby, L., Wrobel, C., Hardin, E., Thibodeau, J., Drazner, M., Peltz, M., Farr, M., Grodin, J., and Hendren, N.
- Published
- 2024
- Full Text
- View/download PDF
18. Applying Knowledge and Confidence Information to Predict Achievement in Forecasting
- Author
-
Miller, S., primary, Kirlik, A., additional, and Hendren, N., additional
- Published
- 2011
- Full Text
- View/download PDF
19. (1291) - Complex Management of a Young Cardiomyopathy Patient Leading to Durable LVAD.
- Author
-
Tan, Y., Malik, T., Hendren, N., Hardin, E., Teotia, S., Reznik, S., Farr, M., and Peltz, M.
- Subjects
- *
HEART assist devices , *CARDIOMYOPATHIES - Published
- 2024
- Full Text
- View/download PDF
20. Survival of the Unfittest: The Longest Living LVAD-Supported Patient with DMD-Associated Cardiomyopathy.
- Author
-
Godfrey, S., Araj, F., Hendren, N., Amin, A., Hardin, E., Garg, S., Grodin, J., Morlend, R., Thibodeau, J., Peltz, M., Drazner, M., Farr, M., and Mammen, P.
- Subjects
- *
HEART assist devices , *CARDIOMYOPATHIES , *DUCHENNE muscular dystrophy , *INTRA-aortic balloon counterpulsation , *CARDIAC magnetic resonance imaging , *NEUROMUSCULAR diseases , *MEDICAL literature , *CARDIOGENIC shock - Abstract
Duchenne muscular dystrophy (DMD) is a X-linked recessive neuromuscular disorder due to mutations in the DMD gene, leading to progressive loss of muscular function. Heart failure is the leading cause of death for DMD patients. There are little long-term data regarding advanced therapies in this population. We present a patient with DMD-associated cardiomyopathy who has survived for >9 years post-LVAD implantation. An 18-year-old male with DMD complicated by quadriparesis, cardiomyopathy, and moderate restrictive lung disease presented to UT Southwestern Medical Center with inotrope-dependent, end-stage heart failure in cardiogenic shock in 2013. Cardiac MRI showed severe bilateral chamber enlargement and dysfunction (LVEF 15%, RVEF 26%). While on milrinone 0.5mcg/kg/min, his intracardiac hemodynamics were evident for elevated ventricular-filling pressures and low cardiac index (Table 1). He underwent an uncomplicated HeartWare LVAD implantation through median sternotomy, avoiding disruption of the diaphragm as occurs with other LVADs. His end-organ markers normalized, and he was weaned from inotropic support prior to discharge. Since LVAD implantation, the patient has had an average of 3 hospitalizations per year, mostly for supratherapeutic INR, respiratory infections, and hypovolemia. He has had no driveline infections, stroke, pump thrombosis, or other associated LVAD complications. He only uses his ventilator at night to rest his diaphragm and does not require enteric feeding. To the best of our knowledge, this report represents the longest time on durable LVAD support by a patient with DMD in the medical literature to date. Although cardiomyopathy is the leading cause of death in DMD patients, this no longer must be the case in appropriately selected patients for VAD therapy. As device technology and hemocompatibility continue to evolve, VAD therapy can offer a potential survival advantage in this patient population with minimal complications. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. (829) - The Forgotten Pump - Waitlist & Post-Transplant Outcomes of Heart Transplant Recipients Supported by Heartware HVAD Before & After Device Recall.
- Author
-
Hussain, F., Jawaid, A., Morlend, R., Thomas, M., Hendren, N., Weston, J., Heid, C., Ginder, K., Hardin, E., Araj, F., Farr, M., Peltz, M., and Truby, L.
- Subjects
- *
HEART transplant recipients , *TREATMENT effectiveness , *HEART assist devices - Published
- 2024
- Full Text
- View/download PDF
22. (1192) - Pulseless Paradoxus in a Heartmate3 Recipient with Cardiac Tamponade.
- Author
-
Beaini, H., Hussain, F., Jawaid, A., Truby, L., Ginder, K., Zimmerman, R., Waller, S., Josey, A., Goral, M., Thomas, M., Varghese, D., Edwards, M., Hendren, N., Peltz, M., Farr, M., and Araj, F.
- Subjects
- *
CARDIAC tamponade - Published
- 2024
- Full Text
- View/download PDF
23. (341) - Association of HLA Mismatch and Treatment for Rejection within the First Year After Heart Transplantation.
- Author
-
Truby, L.K., Jawaid, A., Hussain, F., Wrobel, C., Hendren, N., Garg, S., Morlend, R., Beaini, H., Hardin, E., Araj, F., Thibodeau, J.T., Drazner, M., Grodin, J.L., Lacelle, C., Peltz, M., and Farr, M.
- Subjects
- *
HEART transplantation - Published
- 2024
- Full Text
- View/download PDF
24. (30) - Glucagon-Like Peptide-1 Agonist Use for Obesity Treatment in Patients with Left Ventricular Assist Devices.
- Author
-
Edwards, M., Thomas, M., Varghese, D., Truby, L., Wrobel, C., Hardin, E., Thibodeau, J., Drazner, M., Peltz, M., Farr, M., Grodin, J., and Hendren, N.
- Subjects
- *
GLUCAGON-like peptide-1 agonists , *HEART assist devices , *OBESITY , *THERAPEUTICS - Published
- 2024
- Full Text
- View/download PDF
25. Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis
- Author
-
Enrico Ammirati, Laura Lupi, Matteo Palazzini, Nicholas S. Hendren, Justin L. Grodin, Carlo V. Cannistraci, Matthieu Schmidt, Guillaume Hekimian, Giovanni Peretto, Thomas Bochaton, Ahmad Hayek, Nicolas Piriou, Sergio Leonardi, Stefania Guida, Annalisa Turco, Simone Sala, Aitor Uribarri, Caroline M. Van de Heyning, Massimo Mapelli, Jeness Campodonico, Patrizia Pedrotti, Maria Isabel Barrionuevo Sánchez, Albert Ariza Sole, Marco Marini, Maria Vittoria Matassini, Mickael Vourc’h, Antonio Cannatà, Daniel I. Bromage, Daniele Briguglia, Jorge Salamanca, Pablo Diez-Villanueva, Jukka Lehtonen, Florent Huang, Stéphanie Russel, Francesco Soriano, Fabrizio Turrini, Manlio Cipriani, Manuela Bramerio, Mattia Di Pasquale, Aurelia Grosu, Michele Senni, Davide Farina, Piergiuseppe Agostoni, Stefania Rizzo, Monica De Gaspari, Francesca Marzo, Jason M. Duran, Eric D. Adler, Cristina Giannattasio, Cristina Basso, Theresa McDonagh, Mathieu Kerneis, Alain Combes, Paolo G. Camici, James A. de Lemos, Marco Metra, Ammirati, E, Lupi, L, Palazzini, M, Hendren, N, Grodin, J, Cannistraci, C, Schmidt, M, Hekimian, G, Peretto, G, Bochaton, T, Hayek, A, Piriou, N, Leonardi, S, Guida, S, Turco, A, Sala, S, Uribarri, A, Van De Heyning, C, Mapelli, M, Campodonico, J, Pedrotti, P, Barrionuevo Sanchez, M, Ariza Sole, A, Marini, M, Matassini, M, Vourc'H, M, Cannata, A, Bromage, D, Briguglia, D, Salamanca, J, Diez-Villanueva, P, Lehtonen, J, Huang, F, Russel, S, Soriano, F, Turrini, F, Cipriani, M, Bramerio, M, Di Pasquale, M, Grosu, A, Senni, M, Farina, D, Agostoni, P, Rizzo, S, De Gaspari, M, Marzo, F, Duran, J, Adler, E, Giannattasio, C, Basso, C, Mcdonagh, T, Kerneis, M, Combes, A, Camici, P, De Lemos, J, Metra, M, CarMeN, laboratoire, Niguarda Hospital [Milan, Italy], University of Brescia, University of Texas Southwestern Medical Center [Dallas], Tsinghua University [Beijing] (THU), Center for Systems Biology Dresden [Dresden, Germany] (CSBD), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hospices Civils de Lyon (HCL), Université de Lyon, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Università degli Studi di Pavia = University of Pavia (UNIPV), Fondazione IRCCS Policlinico San Matteo [Pavia], Hospital Clinico Universitario de Valladolid [Castilla y León, Spain] (HCUV), Instituto de Salud Carlos III [Madrid] (ISC), University of Antwerp (UA), Università degli Studi di Milano = University of Milan (UNIMI), IRCCS Istituto Nazionale dei Tumori [Milano], Bellvitge University Hospital [Barcelona, Spain], Presidio Ospedaliero 'G. Salesi' AN = Ancona Hospital Salesi [Ancona, Italy] (POGSA-AHS), Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Centre hospitalier universitaire de Nantes (CHU Nantes), Thérapeutiques cliniques et expérimentales des infections (EA 3826) (EA 3826), Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), King‘s College London, King's College Hospital (KCH), Mater Domini Humanitas Hospital [Castellanza, Italy] (MD2H), Hospital Universitario de La Princesa, Helsinki University Hospital [Finland] (HUS), Hôpital Foch [Suresnes], Ospedale Civile di Baggiovara [Modena, Italy] (OCB), Hospital Papa Giovanni XXIII (Hosp P Giovanni XXIII), Azienda Ospedale Università di Padova = Hospital-University of Padua (AOUP), Ospedale 'Infermi' di Rimini [Rimini, Italy] (OIR), University of California [San Diego] (UC San Diego), University of California (UC), and Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB)
- Subjects
Adult ,Male ,outcome ,SARS-CoV-2 ,cardiac ,[SDV]Life Sciences [q-bio] ,Left ,COVID-2019 ,MRI ,myocarditis ,Female ,Humans ,Prevalence ,Retrospective Studies ,Stroke Volume ,Ventricular Function, Left ,COVID-19 ,Myocarditis ,[SDV] Life Sciences [q-bio] ,myocarditi ,Physiology (medical) ,Ventricular Function ,Human medicine ,Cardiology and Cardiovascular Medicine - Abstract
Background: Acute myocarditis (AM) is thought to be a rare cardiovascular complication of COVID-19, although minimal data are available beyond case reports. We aim to report the prevalence, baseline characteristics, in-hospital management, and outcomes for patients with COVID-19–associated AM on the basis of a retrospective cohort from 23 hospitals in the United States and Europe. Methods: A total of 112 patients with suspected AM from 56 963 hospitalized patients with COVID-19 were evaluated between February 1, 2020, and April 30, 2021. Inclusion criteria were hospitalization for COVID-19 and a diagnosis of AM on the basis of endomyocardial biopsy or increased troponin level plus typical signs of AM on cardiac magnetic resonance imaging. We identified 97 patients with possible AM, and among them, 54 patients with definite/probable AM supported by endomyocardial biopsy in 17 (31.5%) patients or magnetic resonance imaging in 50 (92.6%). We analyzed patient characteristics, treatments, and outcomes among all COVID-19–associated AM. Results: AM prevalence among hospitalized patients with COVID-19 was 2.4 per 1000 hospitalizations considering definite/probable and 4.1 per 1000 considering also possible AM. The median age of definite/probable cases was 38 years, and 38.9% were female. On admission, chest pain and dyspnea were the most frequent symptoms (55.5% and 53.7%, respectively). Thirty-one cases (57.4%) occurred in the absence of COVID-19–associated pneumonia. Twenty-one (38.9%) had a fulminant presentation requiring inotropic support or temporary mechanical circulatory support. The composite of in-hospital mortality or temporary mechanical circulatory support occurred in 20.4%. At 120 days, estimated mortality was 6.6%, 15.1% in patients with associated pneumonia versus 0% in patients without pneumonia ( P =0.044). During hospitalization, left ventricular ejection fraction, assessed by echocardiography, improved from a median of 40% on admission to 55% at discharge (n=47; P Conclusions: AM occurrence is estimated between 2.4 and 4.1 out of 1000 patients hospitalized for COVID-19. The majority of AM occurs in the absence of pneumonia and is often complicated by hemodynamic instability. AM is a rare complication in patients hospitalized for COVID-19, with an outcome that differs on the basis of the presence of concomitant pneumonia.
- Published
- 2022
- Full Text
- View/download PDF
26. Biomarker-Based Assessment for Infectious Risk Before and After Heart Transplantation.
- Author
-
Huang AL, Hendren N, Carter S, Larsen C, Garg S, La Hoz R, and Farr M
- Subjects
- Biomarkers, Humans, Viral Load methods, Heart Failure surgery, Heart Transplantation adverse effects, Torque teno virus genetics
- Abstract
Purpose of Review: Survival outcomes for heart transplant recipients have improved in recent decades, but infection remains a significant cause of morbidity and mortality. In this review, we discuss several biological markers, or biomarkers, that may be used to monitor immunologic status in this patient population., Recent Findings: While modest, data on the utility of immune biomarkers in heart transplant recipients suggest correlation between low level of immune response and increased infection risk. More novel assays, such as the detection of circulating levels of pathogen cell-free DNA in plasma and the use of Torque teno virus load as a surrogate for net state of immunosuppression, have potential to be additional important biomarkers. Biomarker approaches to individualize immunosuppression therapy among heart transplant recipients is a promising area of medicine. However, additional studies are needed to inform the optimal protocol in which to incorporate these biomarkers into clinical practice., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
27. Social capital I: measurement and associations with economic mobility.
- Author
-
Chetty R, Jackson MO, Kuchler T, Stroebel J, Hendren N, Fluegge RB, Gong S, Gonzalez F, Grondin A, Jacob M, Johnston D, Koenen M, Laguna-Muggenburg E, Mudekereza F, Rutter T, Thor N, Townsend W, Zhang R, Bailey M, Barberá P, Bhole M, and Wernerfelt N
- Subjects
- Adult, Child, Community-Institutional Relations, Datasets as Topic, Geographic Mapping, Humans, Poverty statistics & numerical data, Racism, Social Media statistics & numerical data, Social Support, United States, Volunteers, Economic Status statistics & numerical data, Friends, Income statistics & numerical data, Social Capital, Social Mobility statistics & numerical data
- Abstract
Social capital-the strength of an individual's social network and community-has been identified as a potential determinant of outcomes ranging from education to health
1-8 . However, efforts to understand what types of social capital matter for these outcomes have been hindered by a lack of social network data. Here, in the first of a pair of papers9 , we use data on 21 billion friendships from Facebook to study social capital. We measure and analyse three types of social capital by ZIP (postal) code in the United States: (1) connectedness between different types of people, such as those with low versus high socioeconomic status (SES); (2) social cohesion, such as the extent of cliques in friendship networks; and (3) civic engagement, such as rates of volunteering. These measures vary substantially across areas, but are not highly correlated with each other. We demonstrate the importance of distinguishing these forms of social capital by analysing their associations with economic mobility across areas. The share of high-SES friends among individuals with low SES-which we term economic connectedness-is among the strongest predictors of upward income mobility identified to date10,11 . Other social capital measures are not strongly associated with economic mobility. If children with low-SES parents were to grow up in counties with economic connectedness comparable to that of the average child with high-SES parents, their incomes in adulthood would increase by 20% on average. Differences in economic connectedness can explain well-known relationships between upward income mobility and racial segregation, poverty rates, and inequality12-14 . To support further research and policy interventions, we publicly release privacy-protected statistics on social capital by ZIP code at https://www.socialcapital.org ., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
28. Social capital II: determinants of economic connectedness.
- Author
-
Chetty R, Jackson MO, Kuchler T, Stroebel J, Hendren N, Fluegge RB, Gong S, Gonzalez F, Grondin A, Jacob M, Johnston D, Koenen M, Laguna-Muggenburg E, Mudekereza F, Rutter T, Thor N, Townsend W, Zhang R, Bailey M, Barberá P, Bhole M, and Wernerfelt N
- Subjects
- Datasets as Topic, Humans, Income statistics & numerical data, Prejudice statistics & numerical data, Social Media statistics & numerical data, United States, Universities statistics & numerical data, Economic Status statistics & numerical data, Friends, Geographic Mapping, Schools statistics & numerical data, Social Capital, Social Class, Students statistics & numerical data
- Abstract
Low levels of social interaction across class lines have generated widespread concern
1-4 and are associated with worse outcomes, such as lower rates of upward income mobility4-7 . Here we analyse the determinants of cross-class interaction using data from Facebook, building on the analysis in our companion paper7 . We show that about half of the social disconnection across socioeconomic lines-measured as the difference in the share of high-socioeconomic status (SES) friends between people with low and high SES-is explained by differences in exposure to people with high SES in groups such as schools and religious organizations. The other half is explained by friending bias-the tendency for people with low SES to befriend people with high SES at lower rates even conditional on exposure. Friending bias is shaped by the structure of the groups in which people interact. For example, friending bias is higher in larger and more diverse groups and lower in religious organizations than in schools and workplaces. Distinguishing exposure from friending bias is helpful for identifying interventions to increase cross-SES friendships (economic connectedness). Using fluctuations in the share of students with high SES across high school cohorts, we show that increases in high-SES exposure lead low-SES people to form more friendships with high-SES people in schools that exhibit low levels of friending bias. Thus, socioeconomic integration can increase economic connectedness in communities in which friending bias is low. By contrast, when friending bias is high, increasing cross-SES interactions among existing members may be necessary to increase economic connectedness. To support such efforts, we release privacy-protected statistics on economic connectedness, exposure and friending bias for each ZIP (postal) code, high school and college in the United States at https://www.socialcapital.org ., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
29. Association of Kidney Disease With Outcomes in COVID-19: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry.
- Author
-
Rao A, Ranka S, Ayers C, Hendren N, Rosenblatt A, Alger HM, Rutan C, Omar W, Khera R, Gupta K, Mody P, DeFilippi C, Das SR, Hedayati SS, and de Lemos JA
- Subjects
- Aged, Aged, 80 and over, COVID-19 diagnosis, COVID-19 therapy, Cardiovascular Diseases diagnosis, Cardiovascular Diseases therapy, Cause of Death, Female, Hospitalization, Humans, Male, Middle Aged, Prognosis, Registries, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic therapy, Risk Assessment, Risk Factors, Time Factors, United States, COVID-19 mortality, Cardiovascular Diseases mortality, Renal Insufficiency, Chronic mortality
- Abstract
Background Emerging evidence links acute kidney injury (AKI) in patients with COVID-19 with higher mortality and respiratory morbidity, but the relationship of AKI with cardiovascular disease outcomes has not been reported in this population. We sought to evaluate associations between chronic kidney disease (CKD), AKI, and mortality and cardiovascular outcomes in patients hospitalized with COVID-19. Methods and Results In a large multicenter registry including 8574 patients with COVID-19 from 88 US hospitals, data were collected on baseline characteristics and serial laboratory data during index hospitalization. Primary exposure variables were CKD (categorized as no CKD, CKD, and end-stage kidney disease) and AKI (classified into no AKI or stages 1, 2, or 3 using a modification of the Kidney Disease Improving Global Outcomes guideline definition). The primary outcome was all-cause mortality. The key secondary outcome was major adverse cardiac events, defined as cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, new-onset nonfatal heart failure, and nonfatal cardiogenic shock. CKD and end-stage kidney disease were not associated with mortality or major adverse cardiac events after multivariate adjustment. In contrast, AKI was significantly associated with mortality (stage 1 hazard ratio [HR], 1.72 [95% CI, 1.46-2.03]; stage 2 HR, 1.83 [95% CI, 1.52-2.20]; stage 3 HR, 1.69 [95% CI, 1.44-1.98]; versus no AKI) and major adverse cardiac events (stage 1 HR, 2.17 [95% CI, 1.74-2.71]; stage 2 HR, 2.70 [95% CI, 2.07-3.51]; stage 3 HR, 3.06 [95% CI, 2.52-3.72]; versus no AKI). Conclusions This large study demonstrates a significant association between AKI and all-cause mortality and, for the first time, major adverse cardiovascular events in patients hospitalized with COVID-19.
- Published
- 2021
- Full Text
- View/download PDF
30. Striking Similarities of Multisystem Inflammatory Syndrome in Children and a Myocarditis-Like Syndrome in Adults: Overlapping Manifestations of COVID-19.
- Author
-
Most ZM, Hendren N, Drazner MH, and Perl TM
- Subjects
- Adult, Child, Child, Preschool, Female, Humans, Male, Syndrome, COVID-19 metabolism, COVID-19 pathology, Myocarditis metabolism, Myocarditis pathology, SARS-CoV-2 metabolism, Systemic Inflammatory Response Syndrome metabolism, Systemic Inflammatory Response Syndrome pathology
- Published
- 2021
- Full Text
- View/download PDF
31. The Value of Medicaid: Interpreting Results from the Oregon Health Insurance Experiment.
- Author
-
Finkelstein A, Hendren N, and Luttmer EFP
- Abstract
We develop a set of frameworks for welfare analysis of Medicaid and apply them to the Oregon Health Insurance Experiment, a Medicaid expansion for low-income, uninsured adults that occurred via random assignment. Across different approaches, we estimate recipient willingness to pay for Medicaid between $0.5 and $1.2 per dollar of the resource cost of providing Medicaid; estimates of the expected transfer Medicaid provides to recipients are relatively stable across approaches, but estimates of its additional value from risk protection are more variable. We also estimate that the resource cost of providing Medicaid to an additional recipient is only 40% of Medicaid's total cost; 60% of Medicaid spending is a transfer to providers of uncompensated care for the low-income uninsured.
- Published
- 2019
- Full Text
- View/download PDF
32. Subsidizing Health Insurance for Low-Income Adults: Evidence from Massachusetts.
- Author
-
Finkelstein A, Hendren N, and Shepard M
- Subjects
- Adult, Humans, Insurance Coverage, Massachusetts, Models, Theoretical, Consumer Behavior economics, Cost Sharing economics, Income, Insurance, Health economics, Poverty
- Abstract
How much are low- income individuals willing to pay for health insurance, and what are the implications for insurance markets? Using administrative data from Massachusetts’ subsidized insurance exchange, we exploit discontinuities in the subsidy schedule to estimate willingness to pay and costs of insurance among low- income adults. As subsidies decline, insurance take- up falls rapidly, dropping about 25 percent for each $40 increase in monthly enrollee premiums. Marginal enrollees tend to be lower- cost, indicating adverse selection into insurance. But across the entire distribution we can observe (approximately the bottom 70 percent of the willingness to pay distribution) enrollees’ willingness to pay is always less than half of their own expected costs that they impose on the insurer. As a result, we estimate that take- up will be highly incomplete even with generous subsidies. If enrollee premiums were 25 percent of insurers’ average costs, at most half of potential enrollees would buy insurance; even premiums subsidized to 10 percent of average costs would still leave at least 20 percent uninsured. We briefly consider potential explanations for these findings and their normative implications.
- Published
- 2019
33. Resolution of acute hepatitis B-associated aplastic anaemia with antiviral therapy.
- Author
-
Hendren N, Moore J, Hofmann S, and Rambally S
- Subjects
- Adult, Anemia, Aplastic virology, Female, Hepatitis B drug therapy, Humans, Treatment Outcome, Anemia, Aplastic drug therapy, Antiviral Agents therapeutic use, Hepatitis B complications, Tenofovir therapeutic use
- Abstract
A previously healthy 44-year-old woman presented with 3 days of worsening petechial rash, epistaxis and fatigue. Admission labs revealed pancytopenia, low reticulocyte index and elevated liver enzymes. Bone marrow biopsy demonstrated a profoundly hypocellular bone marrow without dysplasia and additional testing demonstrated an acute hepatitis B infection. In the context of an acute hepatitis B infection, elevated liver enzymes and aplastic anaemia, our patient was diagnosed with severe hepatitis-associated aplastic anaemia due to an acute hepatitis B infection. She was initiated on antiviral therapy with tenofovir and briefly received immunosuppressive therapy with a robust sustained improvement in her blood counts. Acute hepatitis B-associated aplastic anaemia is an exceptionally rare presentation of aplastic anaemia. We present acute hepatitis B-associated aplastic anaemia that resolved with antiviral therapy, which to our knowledge is the second such case reported in the literature and the first using tenofovir., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)
- Published
- 2017
- Full Text
- View/download PDF
34. Disseminated histoplasmosis presenting as multiple oral ulcers.
- Author
-
Hendren N, Yek C, Mull J, and Cutrell JB
- Subjects
- AIDS-Related Opportunistic Infections blood, AIDS-Related Opportunistic Infections complications, Diagnosis, Differential, Female, Histoplasmosis blood, Histoplasmosis complications, Humans, Middle Aged, Oral Ulcer etiology, AIDS-Related Opportunistic Infections diagnosis, HIV Infections, Hepatitis B, Histoplasmosis diagnosis
- Abstract
A 61-year-old female with a history of advanced HIV disease and chronic hepatitis B was presented with an 8-week history of painful oral ulcers. She appeared systemically well but examination revealed multiple well-demarcated clean-based ulcers on the tongue and hard palate. Biopsy of one of the lesions showed numerous histiocytes containing intracellular yeast forms consistent with Histoplasma capsulatum var. capsulatum Fungal blood cultures subsequently grew H. capsulatum var. capsulatum , confirming a diagnosis of disseminated histoplasmosis. She was treated with intravenous amphotericin B for 2 weeks followed by a prolonged course of oral itraconazole, with which her ulcers resolved completely and have not recurred. This case exemplifies how oral ulcers may be a manifestation of an underlying systemic disease and demonstrates the utility of biopsy in establishing a diagnosis., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)
- Published
- 2017
- Full Text
- View/download PDF
35. Vibrio vulnificus septic shock due to a contaminated tattoo.
- Author
-
Hendren N, Sukumar S, and Glazer CS
- Subjects
- Adult, Anti-Bacterial Agents administration & dosage, Cellulitis drug therapy, Cellulitis physiopathology, Doxycycline administration & dosage, Fatal Outcome, Humans, Male, Shock, Septic drug therapy, Shock, Septic physiopathology, Swimming, Vibrio Infections drug therapy, Vibrio Infections physiopathology, Cellulitis microbiology, Liver Cirrhosis complications, Seawater microbiology, Shock, Septic microbiology, Tattooing adverse effects, Vibrio Infections microbiology, Vibrio vulnificus pathogenicity
- Abstract
We present a case of Vibrio vulnificus septic shock and cellulitis in a patient with chronic liver disease that occurred after obtaining a leg tattoo with subsequent seawater exposure in the Gulf of Mexico. Initial suspicion for V. vulnificus was high and he was started on empiric doxycycline and ceftriaxone at admission. Blood and wound cultures grew oxidase positive and comma-shaped Gram-negative rods ultimately confirmed to be V. vulnificus. Despite aggressive initial treatment, the patient developed septic shock and died. This case highlights the association of chronic liver disease and high mortality associated with infections of V. vulnificus Health providers should remain vigilant for V. vulnificus infections in patients with chronic liver disease and raw oyster ingestion or seawater exposure., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)
- Published
- 2017
- Full Text
- View/download PDF
36. The fading American dream: Trends in absolute income mobility since 1940.
- Author
-
Chetty R, Grusky D, Hell M, Hendren N, Manduca R, and Narang J
- Abstract
We estimated rates of "absolute income mobility"-the fraction of children who earn more than their parents-by combining data from U.S. Census and Current Population Survey cross sections with panel data from de-identified tax records. We found that rates of absolute mobility have fallen from approximately 90% for children born in 1940 to 50% for children born in the 1980s. Increasing Gross Domestic Product (GDP) growth rates alone cannot restore absolute mobility to the rates experienced by children born in the 1940s. However, distributing current GDP growth more equally across income groups as in the 1940 birth cohort would reverse more than 70% of the decline in mobility. These results imply that reviving the "American dream" of high rates of absolute mobility would require economic growth that is shared more broadly across the income distribution., (Copyright © 2017, American Association for the Advancement of Science.)
- Published
- 2017
- Full Text
- View/download PDF
37. The Effects of Exposure to Better Neighborhoods on Children: New Evidence from the Moving to Opportunity Experiment.
- Author
-
Chetty R, Hendren N, and Katz LF
- Subjects
- Adolescent, Birth Rate, Child, Child, Preschool, Educational Status, Female, Humans, Illegitimacy, Marriage, Pregnancy, United States, Young Adult, Housing, Income, Poverty, Residence Characteristics, Social Determinants of Health economics, Social Determinants of Health statistics & numerical data, Social Mobility
- Abstract
The Moving to Opportunity (MTO) experiment offered randomly selected families housing vouchers to move from high-poverty housing projects to lower-poverty neighborhoods. We analyze MTO's impacts on children's long-term outcomes using tax data. We find that moving to a lower-poverty neighborhood when young (before age 13) increases college attendance and earnings and reduces single parenthood rates. Moving as an adolescent has slightly negative impacts, perhaps because of disruption effects. The decline in the gains from moving with the age when children move suggests that the duration of exposure to better environments during childhood is an important determinant of children’s long-term outcomes.
- Published
- 2016
- Full Text
- View/download PDF
38. Intravenous Followed by X-ray Fused with MRI-Guided Transendocardial Mesenchymal Stem Cell Injection Improves Contractility Reserve in a Swine Model of Myocardial Infarction.
- Author
-
Schmuck EG, Koch JM, Hacker TA, Hatt CR, Tomkowiak MT, Vigen KK, Hendren N, Leitzke C, Zhao YQ, Li Z, Centanni JM, Hei DJ, Schwahn D, Kim J, Hematti P, and Raval AN
- Subjects
- Animals, Arrhythmias, Cardiac diagnosis, Cell Separation methods, Endocardium, Hemodynamics, Injections methods, Injections, Intravenous, Myocardial Infarction pathology, Random Allocation, Swine, Magnetic Resonance Imaging, Mesenchymal Stem Cell Transplantation methods, Mesenchymal Stem Cells radiation effects, Myocardial Contraction physiology, Myocardial Infarction surgery
- Abstract
The aim of this study is to determine the effects of early intravenous (IV) infusion later followed by transendocardial (TE) injection of allogeneic mesenchymal stem cells (MSCs) following myocardial infarction (MI). Twenty-four swine underwent balloon occlusion reperfusion MI and were randomized into 4 groups: IV MSC (or placebo) infusion (post-MI day 2) and TE MSC (or placebo) injection targeting the infarct border with 2D X-ray fluoroscopy fused to 3D magnetic resonance (XFM) co-registration (post-MI day 14). Continuous ECG recording, MRI, and invasive pressure-volume analyses were performed. IV MSC plus TE MSC treated group was superior to other groups for contractility reserve (p = 0.02) and freedom from VT (p = 0.03) but had more lymphocytic foci localized to the peri-infarct region (p = 0.002). No differences were observed in post-MI remodeling parameters. IV followed by XFM targeted TE MSC therapy improves contractility reserve and suppresses VT but does not affect post-MI remodeling and may cause an immune response., Competing Interests: The authors declare that they have no competing interests.
- Published
- 2015
- Full Text
- View/download PDF
39. The Great Equalizer: Health Care Access and Infant Mortality in Thailand.
- Author
-
Gruber J, Hendren N, and Townsend RM
- Abstract
This paper analyzes Thailand's 2001 healthcare reform, "30 Baht". The program increased funding available to hospitals to care for the poor and reduced copays to 30 Baht (~$0.75). Our estimates suggest the supply-side funding of the program increased healthcare utilization, especially amongst the poor. Moreover, we find significant impacts on infant mortality: prior to 30 Baht poorer provinces had significantly higher infant mortality rates than richer provinces. After 30 Baht this correlation evaporates to zero. The results suggest that increased access to healthcare among the poor can significantly reduce their infant mortality rates.
- Published
- 2014
- Full Text
- View/download PDF
40. Private Information and Insurance Rejections.
- Author
-
Hendren N
- Abstract
Across a wide set of non-group insurance markets, applicants are rejected based on observable, often high-risk, characteristics. This paper argues that private information, held by the potential applicant pool, explains rejections. I formulate this argument by developing and testing a model in which agents may have private information about their risk. I first derive a new no-trade result that theoretically explains how private information could cause rejections. I then develop a new empirical methodology to test whether this no-trade condition can explain rejections. The methodology uses subjective probability elicitations as noisy measures of agents beliefs. I apply this approach to three non-group markets: long-term care, disability, and life insurance. Consistent with the predictions of the theory, in all three settings I find significant amounts of private information held by those who would be rejected; I find generally more private information for those who would be rejected relative to those who can purchase insurance; and I show it is enough private information to explain a complete absence of trade for those who would be rejected. The results suggest private information prevents the existence of large segments of these three major insurance markets.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.